We’ve just launched a new portal to help you explore stocks, crypto, ETFs, and more data

ONTX

1.49000 USD
0.01
0.67%
Last update Apr 23, 3:59 PM EDT
Pre-market
Day range
1.40000
1.52000
Previous close
1.5
Open
1.47000
Access this stock data via API
Subscribe
Onconova Therapeutics Inc
1.49
0.01
0.67%

Overview

Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

About

CEO
Dr. Steven M. Fruchtman M.D.
Employees
16
Address
12 Penns Trail
Newtown, 18940, PA
United States
Phone
267 759 3680
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNCM
Pre-market

Exchange is currently open for pre-market.
Main market opens in 1 hour 45 minutes

07:44
00:00
09:30
16:00
23:59

Trading Hours (Monday - Friday):

Pre-market
04:00 - 09:30
Main market
09:30 - 16:00
Post-market
16:00 - 20:00
All times are displayed in the America/New_York timezone (EDT, UTC-04:00).